Related Experiment Videos
[In vitro antibacterial activity of ceftizoxime on Pasteurella and EF4]
Abstract:
The in vitro activity of ceftizoxime, a new third-generation cephalosporin, was tested by determining minimal inhibitory concentrations (MIC) by agar dilution method, for 150 strains of genus Pasteurella and group EF4 bacteria from various sources. All the strains were susceptible to ceftizoxime and inhibited by 0.03 micrograms/ml concentration. No significant difference appeared between the 7 species and human and animal strains. Group EF4 bacteria, frequently isolated from animal bite wounds in humans, had higher MIC (O.25-1 micrograms/ml). Results were compared to those obtained with cefotaxime, cephalothin, penicillin G and ampicillin.
Insights
Ceftizoxime, a third-generation cephalosporin, demonstrated potent in vitro activity against Pasteurella and EF4 bacteria. All tested strains were susceptible, showing efficacy against common pathogens found in animal-related infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Genus Pasteurella and group EF4 bacteria are significant pathogens, often associated with animal bite wound infections in humans.
- Understanding the in vitro susceptibility patterns of these bacteria is crucial for guiding antimicrobial therapy.
- Third-generation cephalosporins represent an important class of antibiotics for treating bacterial infections.
Purpose:
- To evaluate the in vitro antimicrobial activity of ceftizoxime against a diverse collection of Pasteurella and EF4 bacterial strains.
- To determine the minimal inhibitory concentrations (MICs) of ceftizoxime for these bacterial groups using the agar dilution method.
- To compare the efficacy of ceftizoxime with other commonly used antibiotics, including cefotaxime, cephalothin, penicillin G, and ampicillin.
Summary:
- Ceftizoxime exhibited excellent in vitro activity against 150 strains of Pasteurella and EF4 bacteria, with all strains inhibited at a concentration of 0.03 µg/ml.
- No significant differences in susceptibility were observed across the seven Pasteurella species or between human and animal isolates.
- Group EF4 bacteria, commonly linked to animal bite wounds, displayed slightly higher MICs ranging from 0.25-1 µg/ml, indicating a need for careful consideration in treatment.
Impact:
- The findings support the potential utility of ceftizoxime as an effective treatment option for infections caused by Pasteurella and EF4 bacteria.
- This study provides valuable data for clinicians and microbiologists in selecting appropriate antimicrobial agents for bite wound infections and other related conditions.
- The comparative analysis highlights the antimicrobial spectrum of ceftizoxime relative to other established antibiotics, aiding in therapeutic decision-making.